Chief Executive Officer LEDERMAN SETH acquired 20,000 shares of Tonix Pharmaceuticals Holding Corp. [TNXP]

The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Tonix Pharmaceuticals Holding Corp. shares valued at $34,200 were purchased by LEDERMAN SETH on Jun 29. At $1.71 per share, LEDERMAN SETH acquired 20,000 shares. The insider’s holdings grew to 24,235 shares worth approximately $43623.0 following the completion of this transaction.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Also, LEDERMAN SETH purchased 100,000 shares, netting a total of over 24,500 in proceeds. Following the buying of shares at $0.24 each, the insider now holds 112,177 shares.

Before that, LEDERMAN SETH had added 12,000 shares to its account. In a trade valued at $7,320, the Chief Executive Officer bought Tonix Pharmaceuticals Holding Corp. shares for $0.61 each. Upon closing the transaction, the insider’s holdings increased to 12,000 shares, worth approximately $21918.600000000002.

As published in their initiating research note from Noble Capital Markets on April 18, 2022, Tonix Pharmaceuticals Holding Corp. [TNXP] has been an Outperform. Analysts at ROTH Capital upgraded the stock from ‘”a Neutral”‘ to ‘”a Buy”‘ outlook in a report released in mid April. As of August 18, 2017, ROTH Capital has increased its “Neutral” rating to a “Buy” for TNXP. Earlier on September 07, 2016, ROTH Capital downgraded its rating. Their new recommendation was “a Neutral” for TNXP stock which previously was a “a Buy”.

Analyzing TNXP’s Price Performance

On Thursday, Tonix Pharmaceuticals Holding Corp. [NASDAQ: TNXP] rose 1.69% to $1.80. The stock’s lowest price that day was $1.67, but it reached a high of $1.89 in the same session. During the last five days, there has been a drop of approximately -3.74%. Over the course of the year, Tonix Pharmaceuticals Holding Corp. shares have dropped approximately -84.27%. Shares of the company reached a 52-week high of $13.6000 on 01/04/22 and a 52-week low of $1.1900 on 07/22/22. A 50-day SMA is recorded $1.8114, while a 200-day SMA reached $7.7194. Nevertheless, trading volume fell to 23.5 million shares from 16.6 million shares the previous day.

Support And Resistance Levels for Tonix Pharmaceuticals Holding Corp. (TNXP)

According to the 24-hour chart, there is a support level at 1.6833, which, if violated, would cause prices to drop to 1.5667. In the upper region, resistance lies at 1.9033. The next price resistance is at 2.0067. RSI (Relative Strength Index) is 52.63 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.2305, which suggests the price will decrease in the coming days. Percent R is at 41.90%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.

Is Tonix Pharmaceuticals Holding Corp. subject to short interest?

Stocks of Tonix Pharmaceuticals Holding Corp. saw a sharp steep in short interest on Jul 14, 2022 dropping by -0.79 million shares to 0.77 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 1.56 million shares. A decline of -101.33% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 0.28 of the overall float, the days-to-cover ratio (short ratio) decline to 0.28.

Which companies own the most shares of Tonix Pharmaceuticals Holding Corp. (TNXP)?

According to BlackRock Fund Advisors filings, the company currently owns 959,928 shares, which is about 5.12% of the total TNXP shares outstanding. The investor’s shares have appreciated by 107,898 from its previous 13-F filing of 852030.0 shares. With the completion of the buy transaction, Renaissance Technologies LLC’s stake is now worth $948,022. The Vanguard Group, Inc. reduced a -6.67% interest valued at $0.89 million while Geode Capital Management LLC purchased a 12,958 stake. A total of 23,891 shares of Tonix Pharmaceuticals Holding Corp. were bought by SSgA Funds Management, Inc. during the quarter, and -427,214 were sold by D. E. Shaw & Co. LP. In its current portfolio, Northern Trust Investments, Inc. holds 129,373 shares valued at $0.2 million.

In terms of Tonix Pharmaceuticals Holding Corp. share price expectations, FactSet research, analysts set an average price target of $10.00 in the next 12 months, up nearly 464.97% from the previous closing price of $1.77. Analysts anticipate Tonix Pharmaceuticals Holding Corp. stock to reach $10.00 by 2022, with the lowest price target being $10.00. In spite of this, 1 analysts ranked Tonix Pharmaceuticals Holding Corp. stock as a Buy at the end of 2022. On February 17, 2016, Oppenheimer assigned a price target of “an Outperform” to the stock and reiterated coverage with a $10.

LEAVE A REPLY

Please enter your comment!
Please enter your name here